ClinicalTrials.gg
CompletedNCT06973577Updated May 6, 2026

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

A Phase 3 interventional study of Centanafadine and Placebo in ADHD, Anxiety and Generalized Anxiety, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 47 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.

Enrollment
8th of 20
315 · median 180
Started
2025
with 4 others
Phase 3
10 of 20
3 open now
Registered
14th of 20
by date
Lead sponsor
16 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 8th largest by enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, and was the 14th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About centanafadine

centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants between 18 and 65 years of age, inclusive.
  2. Diagnosis of ADHD per the criteria and confirmed using the ACDS Version 1.2 at screening.
  3. AISRS total score of ≥ 28 at baseline.
  4. Diagnosis of GAD and/or SAD per DSM-5-TR criteria and confirmed using the MINI at screening.
  5. HAM-A total score ≥ 20 at baseline.
  6. CGI-S-ADHD and CGI-S-anxiety rating ≥ 4 at baseline.
  7. from 18.0 to 40.0 kg/m2 (inclusive).
  8. Ability to provide written, prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial.

Exclusion criteria

Exclusion Criteria:

  1. In the clinical opinion of the investigator, participant has not derived therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
  2. In the clinical opinion of the investigator, participant has not derived therapeutic benefit from 2 or more anxiety therapies of 2 different classes (eg, selegiline and duloxetine, or buspirone and lorazepam) given with an acceptable dose and duration during adulthood (aged 18 years or older).
  3. Current use of prohibited psychotropic medications that cannot be discontinued 2 weeks prior to randomization. Fluoxetine is prohibited within 28 days of randomization.
  4. Participants who have started individual or group psychotherapy within the past 3 months prior to screening (ongoing psychotherapy that is not expected to change in frequency or type during the trial is permissible).
  5. Any disorder that is the primary focus of treatment other than ADHD.
  6. Participants with lifetime diagnosis of neurocognitive disorder, schizophrenia or any psychotic disorder, bipolar disorder, autism spectrum disorder, or personality disorders. Participants with current diagnosis of post-traumatic stress disorder, obsessive compulsive disorder, any substance use disorder, eating disorders, major depressive disorder; or other anxiety disorders such as panic disorder, agoraphobia, separation anxiety disorder, selective mutism, substance or medication induced anxiety, or due to medical condition, or specific phobia will be excluded.
  7. Participant is, in the investigator's judgment, at significant risk for suicide. A participant with a Columbia-Suicide Severity Rating Scale (C-SSRS) ideation score of 4 or 5 within the last 6 months or participants who answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) within the past year must be excluded.
  8. Participants with a positive UDS for illicit drugs at screening or baseline. Participants with a positive drug test at screening for ADHD or anxiety medications including methylphenidate, or amphetamines, may continue while undergoing the required . Participants with a positive drug test at baseline for ADHD or anxiety medications are excluded. A positive drug test at baseline for drugs of abuse, including cannabis, unless all of the following cannabis specific conditions are met:

    1. No DSM-5-TR diagnosis of cannabis use disorder within the past 12 months;
    2. If per investigator's judgement, cannabis use will not compromise safety, efficacy assessments or protocol compliance.
    3. Participant agrees to maintain their consistent use pattern throughout the trial
    4. Participant agrees to refrain from cannabis use within 12 hours of trial visits.
  9. Participants with evidence of current substance use disorder or history in the past 12 months.
  10. Participants with epilepsy, a history of epilepsy, or a history of seizure, except for a single childhood febrile seizure, a single seizure post brain injury, or a single seizure due to alcohol withdrawal.
  11. Participants who are partially hospitalized or receiving inpatient care or have any other medical or physical condition(s) that, in the opinion of the investigator, may prevent the participant from completing the trial or would go against the participant's best interest with participation in the trial. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. This would also include most bariatric surgeries, with the only exception being those where there has been no breach of the gastrointestinal wall (ie, uncomplicated lap band surgery) AND no sign of malabsorption.
  12. The following laboratory test and results are exclusionary at screening:

    1. ≤ 75,000/mm3
    2. ≤ 9 g/dL
    3. Neutrophils, absolute ≤ 1000/mm3
    4. > 2 ×
    5. ALT > 2 × upper limit of normal
    6. Creatinine ≥ 2 mg/dL
    7. ≥ 7%
    8. ≥ 450 msec for males or ≥ 470 msec for females
    9. Abnormal free thyroxin (T4), unless discussed with and approved by the medical monitor (Note: free T4 is measured only if result for thyroid stimulating hormone [TSH] is abnormal)
  13. Participants presenting with, or having a history of, uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 95 mmHg) or symptomatic hypotension, or orthostatic hypotension which is defined as a decrease of ≥ 30 mmHg in systolic blood pressure or a decrease of ≥ 20 mmHg in diastolic blood pressure after at least 3 minutes standing compared with the previous supine blood pressure, or development of symptoms.
  14. Participants with a history of any prior exposure to centanafadine.
  15. Participants who have participated in other clinical trials involving drugs within 180 days prior to screening or who have participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
  16. Participants of who are breast-feeding and/or have a positive pregnancy test result prior to receiving IMP.
  17. Participants of / POCBP who do not agree to practice 2 different effective and/or highly effective methods of or remain fully abstinent from sexual activity with the potential for conception, per the guidelines in Section 10.3.
  18. Participants who do not agree to refrain from donating sperm or eggs from trial screening through 90 days for sperm and 30 days for eggs after the last dose of IMP.
  19. Participants who have an allergy to the IMP or any component of the IMP.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
315 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Other: Placebo

  • Experimental
    Centanafadine QD XR fixed dose 328.8mg

    Drug: Centanafadine

Interventions

  • Centanafadine QD XR fixed dose 328.8mg

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in Adult Investigator Symptom Rating Scale (AISRS)

    The AISRS is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Hamilton Anxiety Rating Scale (HAM-A)

    The HAM-A consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a 5-point scale, ranging from 0 = not present to 4 = very severe. Negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 8

07

Study locations

47 sites
  • Clinical Research Site #017 - Harmonex Neuroscience Research
    Dothan, Alabama 36303, United States
  • Clinical Research Center #033 - Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Clinical Research Center #048 - Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • Clinical Research Site #052 - Leading Edge Research LA, LLC
    Encino, California 91316, United States
  • Clinical Research Center #008 - Long Beach Clinical Trial Services Inc.
    Long Beach, California 90806, United States
  • Clinical Research Site #008 - Long Beach Clinical Trial Services Inc.
    Long Beach, California 90806, United States
  • Clinical Research Site #011 - NRC Research Institute
    Orange, California 92868, United States
  • Clinical Research Center #042 - Anderson Clinical Research
    Redlands, California 92374, United States
  • Clinical Research Site #037 - Cenexel CIT IE (Clinical Innovations Inc)
    Riverside, California 92506, United States
  • Clinical Research Site #039 - California Neuroscience Research, LLC
    Sherman Oaks, California 91403, United States
  • Clinical Research Site #038 - Sunwise Clinical Research
    Walnut Creek, California 94596, United States
  • Clinical Research Site #030 - MCB Clinical Research Centers
    Colorado Springs, Colorado 80910, United States
  • Clinical Research Site #045 - Research Center for Clinical Studies
    Norwalk, Connecticut 06851-4903, United States
  • Clinical Research Center #035 - Sarkis Clinical Trials
    Gainesville, Florida 32607-2053, United States
  • Clinical Research Site #005 - Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Clinical Research Site #046 - ARSN-Largo CRU
    Largo, Florida 33777, United States
  • Clinical Research Site #010 - Meridien Research/Accel Clinical
    Maitland, Florida 32751, United States
  • Clinical Research Site #015 - Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Clinical Research Site #006 - CNS Healthcare Orlando
    Orlando, Florida 32801, United States
  • Clinical Research Site #019 - Segal Trials Innovatice Clinical Research, Inc.
    Tamarac, Florida 33319, United States
  • Clinical Research Site #004 - CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • Clinical Research Site #002 - Psych Atlanta, PC
    Marietta, Georgia 30060, United States
  • Clinical Research Center #032 - CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Clinical Research Center #056 - Research Works INC.
    New Orleans, Louisiana 70125, United States
  • Clinical Research Site # 027 - Copley Clinical
    Boston, Massachusetts 02116, United States
  • Clinical Research Center #022 - Boston Clinical Trials - Alcanza Clinical Research, LLC
    Boston, Massachusetts 02132, United States
  • Clinical Research Site #025 - Adams Clinical
    Watertown, Massachusetts 02472, United States
  • Clinical Research Site #016 - Clinical Research of Southern Nevada, LLC
    Las Vegas, Nevada 89128, United States
  • Clinical Research Center #031 - Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Clinical Research Site #026 - Neurobehavioral Research Inc
    Cedarhurst, New York 11516, United States
  • Clinical Research Site #021 - The Medical Research Network, LLC
    New York, New York 10128, United States
  • Clinical Research Site #028 - Patient Priority Clinical Sites LLC
    Cincinnati, Ohio 45215, United States
  • Clinical Research Site #047 - Insight Clinical Trials
    Independence, Ohio 44131, United States
  • Clinical Research Site #009 - Paradigm Research Professionals LLC
    Oklahoma City, Oklahoma 73116, United States
  • Clinical Research Site #023 - Summit Headlands LLC
    Portland, Oregon 97210, United States
  • Clinical Research Site # 029 - Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18103, United States
  • Clinical Research Site #014 - Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Clinical Research Center #059 - Adams Clinical Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Research Center #034 - Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Clinical Research Site #001 - CNS Healthcare - Memphis
    Memphis, Tennessee 38119, United States
  • Clinical Research Site #013 - Donald J. Garcia, Jr. MD., PA
    Austin, Texas 78737, United States
  • Clinical Research Site #020 - Houston Clinical Trials LLC
    Bellaire, Texas 77401, United States
  • Clinical Research Site #003 - FutureSearch Trials of Dallas LP
    Dallas, Texas 75251, United States
  • Clinical Research Site #012 - Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Clinical Research Site #036 - Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • Clinical Research Site #024 - Core Clinical Research
    Everett, Washington 98201, United States
  • Clinical Research Center #062 - Research Works - San Juan
    Guaynabo, PR 00966, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the result of this study will be shared with researchers to achieve aims pre-specified in a methodology sound research proposal. Supporting Information:

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Access Criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: http://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Apr 2026, 12 months.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 12 months is close to that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 15, 2025
StartActual
Mar 26, 2025
Primary completionActual
Apr 22, 2026
CompletionActual
Apr 29, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973577
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Mar 26, 2025
Primary completion
Apr 22, 2026
Completion
Apr 29, 2026
Last update
May 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion